Kerbside

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation

PLAYING THE GOOD HOST
Taj GVK Hotels & Resorts 
BSE Code:532390 
CMP:  Rs190.50

Some big-ticket investors are rumoured to be staking up positions in Taj GVK Hotels & Resorts speculating that some big announcement is likely to be released in the coming days. The stock has seen its volumes jump almost five times compared to its average of the last 10 and 30 weeks. The stock price has also surged higher. Hence, we would recommend momentum traders to enter into this stock with strict stop loss.

KEEPING GOOD HEALTH

Metropolis Healthcare 
BSE Code: 542650
CMP:  Rs1842.75

Diagnostic chain Metropolis Healthcare displayed strong performance in Q3FY20 as it reported a surge of 34.8 per cent in its net profit to  Rs42 crore. Patient visits increased 14 per cent YoY in Q3 to 2.42 million and revenue per patient in Q3FY20 stood at  Rs923 as compared to  Rs898 in Q3FY18, an increase of 2.7 per cent YoY. A few institutional investors are said to be accumulating shares on hopes that the company would continue to post market-leading performance.

PICKING UP SPEED

Larsen & Toubro Infotech
BSE Code: 540005 
CMP:  Rs2017.40

This stock has been gaining a lot of interest among the technical traders and dealers from leading broking firms are indicating that a large number of orders have been executed in this stock by some of the best technical traders of D-Street as they are expecting a spurt in price in the coming trading sessions. You too can jump on to the bandwagon and hope to make a quick buck!

GETTING STRONGER
IOL Chemicals & Pharmaceuticals 
BSE Code: 524164 
CMP:  Rs186.10

The company is one of the leading APIs/bulk drugs companies and is a significant player in the specialty chemicals space with world-class facilities. It has a wide presence across major therapeutic categories like pain management, anti-convulsants, anti-diabetes, anticholesterol and anti-platelets. The company reported its highest quarterly revenue ever for the quarter ended December 31, 2019 and continued its strong operational and financial performance. For the nine months ended December 2019, the company has reported earnings per share of  Rs47.64, compared to earnings per share of  Rs24.03 for nine months ended December 2018. If sources are to be believed, the stock could see a big rerating and the recent rally from the lower levels is just a trailer of the stock’spotential in times ahead.